1. Home
  2. CIF vs IRD Comparison

CIF vs IRD Comparison

Compare CIF & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CIF
  • IRD
  • Stock Information
  • Founded
  • CIF 1988
  • IRD 2018
  • Country
  • CIF United States
  • IRD United States
  • Employees
  • CIF N/A
  • IRD N/A
  • Industry
  • CIF Trusts Except Educational Religious and Charitable
  • IRD
  • Sector
  • CIF Finance
  • IRD
  • Exchange
  • CIF Nasdaq
  • IRD NYSE
  • Market Cap
  • CIF 31.5M
  • IRD 36.1M
  • IPO Year
  • CIF N/A
  • IRD N/A
  • Fundamental
  • Price
  • CIF $1.74
  • IRD $1.15
  • Analyst Decision
  • CIF
  • IRD Strong Buy
  • Analyst Count
  • CIF 0
  • IRD 1
  • Target Price
  • CIF N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • CIF 43.9K
  • IRD 154.1K
  • Earning Date
  • CIF 01-01-0001
  • IRD 02-19-2025
  • Dividend Yield
  • CIF 10.11%
  • IRD N/A
  • EPS Growth
  • CIF N/A
  • IRD N/A
  • EPS
  • CIF N/A
  • IRD N/A
  • Revenue
  • CIF N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • CIF N/A
  • IRD N/A
  • Revenue Next Year
  • CIF N/A
  • IRD $29.37
  • P/E Ratio
  • CIF N/A
  • IRD N/A
  • Revenue Growth
  • CIF N/A
  • IRD N/A
  • 52 Week Low
  • CIF $1.47
  • IRD $0.81
  • 52 Week High
  • CIF $1.77
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • CIF 51.29
  • IRD N/A
  • Support Level
  • CIF $1.72
  • IRD N/A
  • Resistance Level
  • CIF $1.76
  • IRD N/A
  • Average True Range (ATR)
  • CIF 0.02
  • IRD 0.00
  • MACD
  • CIF 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • CIF 62.50
  • IRD 0.00

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: